Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - December 2019

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2019. This month there are two guidelines and two technology appraisals that impact upon primary care.

The Acute kidney injury: prevention, detection and management guideline has been published. It covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.

The Menopause: diagnosis and management guideline has been updated. It covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause. This update includes MHRA safety alert information regarding the risks of breast cancer.

The Cannabidiol with clobazam for treating seizures associated with Dravet syndrome technology appraisal recommends this treatment as an option for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if:

  • the frequency of convulsive seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment
  • the company provides cannabidiol according to the commercial arrangement

The Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome technology appraisal recommends this treatment as an option for treating seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older, only if:

  • the frequency of drop seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment
  • the company provides cannabidiol according to the commercial arrangement

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - December 2019' on Email Share 'NICE Guidance - December 2019' on Delicious Share 'NICE Guidance - December 2019' on Digg Share 'NICE Guidance - December 2019' on Facebook Share 'NICE Guidance - December 2019' on reddit Share 'NICE Guidance - December 2019' on Twitter

atomic-wealth

No Comments to “NICE Guidance - December 2019”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

vipers